Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: Lancet. 2011 May 28;377(9780):1846–1854. doi: 10.1016/S0140-6736(11)60545-X

Table 3.

Adverse events

Control group (n=313) Bevacizumab group (n=313)
Any adverse event 309 (99%) 312 (>99%)
Any serious adverse event 114 (36%) 130 (42%)
Any grade ≥3 adverse event Grade 3/4: 151 (48%);
grade 5: 14 (4%)		 Grade 3/4: 188 (60%);
grade 5: 20 (6%)
Haemorrhage Grade 3/4: 7 (2%) Grade 3/4: 8 (3%); grade 5: 2 (1%)
  Pulmonary haemorrhage Grade 3/4: 1 (<1%) Grade 3/4: 2 (1%); grade 5: 1 (<1%)
  CNS haemorrhage 0 Grade 3/4: 1 (<1%)
Arterial thromboembolic event Grade 3/4: 1 (<1%) Grade 3/4: 10 (3%); grade 5: 2 (1%)
Hypertension Grade 3/4: 4 (1%) Grade 3/4: 15 (5%)
Interstitial lung disease-like events Grade 3/4: 1 (<1%);
grade 5: 1 (<1%)		 Grade 3/4: 1 (<1%); grade 5: 1 (<1%)
Rash Grade 3/4: 19 (6%) Grade 3/4: 49 (16%)

Data are for the safety-assessable patient population. CNS=central nervous system.